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The types of kinins released from purified native, single chain human high and low molecular mass kininogens (HMMKs 
and LMMKs, respectively) by purified human urinary kallikrein were separated by reverse-phase HPLC and quantitated 
by the rat uterus bioassay. [Hy@]-lysyl-bradykinin, a recently discovered kinin, represented up to 58% of the biological 
activity released from 4 individual HMMK preparations purified from 4 different healthy volunteers. In contrast, the 
majority of the biological activity released from LMMKs purified from pooled plasma was identified as Lys-bradykinin 
and [Hy@]-lysyl-bradykinin represented only 6.4 f 3.8%. These findings indicate posttranslational hydroxylation of 
human kininogens and suggest apreference of HMMKs for this modification. 
Kininogen; Kallikrein; Kinin; [He]-lys-bradykinin 
1. INTRODUCTION 
Kinins are a family of potent vasodilator pep- 
tides released by limited proteolysis from their 
plasma precursor proteins, high molecular mass 
and low molecular mass kininogens, by enzymes 
known as kallikreins [l]. It appears that lysyl- 
bradykinin is the major product released from 
both human high and low molecular mass 
kininogens by tissue kallikreins [2], while 
bradykinin is mainly generated from high 
molecular mass kininogens by plasma kallikrein 
]31. 
In addition to these well known kinins, however, 
the presence of modified kinins in human urine [4] 
and in human ovarian carcinoma ascites [5] has 
been reported. Furthermore, we and others have 
isolated another kinin, [Hyp3]-lysyl-bradykinin, 
which could be released from human heat inac- 
tivated plasma by human urinary kallikrein [6], 
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from Cohn’s fraction IV-4 by hog pancreatic 
kallikrein [6,7] and which could also be identified 
in ascitic fluid of the rat and mouse [6]. In these 
reports, the kinin peptides were generated from 
crude substrate sources. It was therefore the aim of 
the present study to use highly purified, native 
human kininogens for characterization of the 
kinins released by human urinary kallikrein. 
2. MATERIALS AND METHODS 
2.1. Preparation of kininogen substrates 
Low molecular mass kininogen (LMMK) was purified as a 
native single chain molecule from pooled human plasma [8] and 
individual human high molecular mass kininogens (HMMKs) 
were purified as native single chain molecules from the plasma 
of four single healthy donors [9]. The purity of the proteins was 
analyzed by SDS gel electrophoresis [lo] and nativity was 
judged by comparing their individual specific activities obtained 
with the homologous enzyme, urinary kallikrein, with those ob- 
tained previously [l]. Each preparation of purified HMWK and 
LMMK contained 0.65-0.72 and 0.8-0.9 mol of kinin per mol 
of substrate, respectively. 
2.2. Incubation conditions and sample preparation 
Human urinary kallikrein (20 ng in 10 and 30 ~1, respective- 
ly), purified from pooled human urine as described 111, was in- 
cubated with approx. 15Opg of the purified substrates (170 ~1) 
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for 30 min at pH 8.5 and 37°C. Incubation was stopped by 
precipitation with 800 ~1 of solution B [ 1 l] which gives a final 
concentration of 64% acetonitrile. After centrifugation at 
5000 x g for 15 min the supernatant was lyophilized, resuspend- 
ed in 250 ~1 solution A [lo] and filtered through a Centricon 
lo-filter (Amicon B.V., Oosterhout, The Netherlands). The 
ultrafiltrate was subjected to reverse-phase HPLC using a 250 
,ul sample loop. Control experiments were performed by incuba- 
tion of standard kinins with the purified substrates in the 
absence of urinary kallikrein. 
kinins upon HPLC separation the majority of the 
biological activity released from purified LMMK 
corresponded to the position of Lys-bradykinin 
(table 1) and another peak of biological activity 
similar to that of the bradykinin standard. In addi- 
tion, a small peak of biological activity which did 
not correspond to the retention time and biological 
activity of any of the standard kinins employed 
eluted in front of the Lys-bradykinin standard. 
2.3. Separation and identification of kinins by HPLC 
The HPLC system consisted of two 114M pumps with con- 
troller, a UV-detector model 160 (all from Beckman In- 
struments) and a Shimadzu CR-3A integrator. A micro- 
Bondapak Cl8 column (3.9 x 300 mm) with guard column was 
employed and elution was performed under isocratic conditions 
as described by Proud [l l] with slight modifications. The flow 
rate was 1 ml/min and fractions of 0.5 ml were collected (Gilson 
fraction collector model 203). The respective retention time, 
biological activity, determined by the rat uterus bioassay [12], 
and immunoreactivity [13] of eluted kinins were determined and 
compared with those of the following standards: Lys- 
bradykinin, bradykinin, Met-Lys-bradykinin, Ile-Ser- 
bradykinin, des-Arg’-bradykinin (Sigma, St. Louis, MO); des- 
Arg’-bradykinin (Serva, Heidelberg, FRG) and [Ala3]-Lys- 
bradykinin (Peninsula Laboratories, Belmont, CA). The 
distribution of released kinins was calculated by comparing the 
biological activity of a particular kinin eluted to the total 
amount of kinin activity eluted from the column. 
2.4. Determination of amino acid sequence 
Using individual high molecular mass kinino- 
gens purified from four different plasma samples 
as substrate for purified human urinary kallikrein, 
the elution profile of the kinins released was 
similar (fig. 1). However, this time the majority of 
the biological activity eluted faster than Lys- 
bradykinin and corresponded to the small uniden- 
tified peak observed when low molecular mass 
kininogen was the substrate. Compared to the 
retention times of all standard kinins employed 
(fig. l), this fast eluting biological activity again did 
not correspond to any of them. Table 1 sum- 
marizes the percentage of kinin distribution from 
four different individual donors from which 
HMMKs have been purified and compares them 
with the data obtained with LMMK purified from 
pooled plasma of multiple donors. 
Amino acid sequence analysis was performed in a gas-phase 
sequencer 470A (Applied Biosystems, Foster City, USA). The 
phenylthiohydantoin derivatives were analysed by an HPLC 
system which separates all components isocratically [14,15]. 
The phenylthiohydantoin derivative of 4-hydroxyproline which 
elutes as a characteristic double peak shortly before alanine was 
added to the reference mixture. 
3. RESULTS 
Compared to the elution pattern of standard 
The fast eluting biological activity of individual 
experiments, which was also immunoreactive, was 
pooled and 150-350 ng (biological activity and im- 
munoreactivity) were subjected to amino acid se- 
quence analysis. The initial yield was between 65 
and 75%, the repetitive yield amounted to about 
95%. The amino acid sequence was similar to Lys- 
bradykinin (kallidin). However, in cycle 4 of the 
sequence degradation the characteristic double 
peak of hydroxyproline was found instead of pro- 
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Table 1 
Percent distribution of biologically active kinins released by human urinary 
kallikrein 
Substrate HMMK LMMK 
Donor 1 2 3 4 
multiple 
[Hyp3]-Lys-BK 55.8i1.6 29.5rt7.2 42.8 f2.6 58.8 6.4rt 3.8 
Lys-BK 39.6k5.1 60.7k8.9 45.1k2.6 39.6 64.0+ 13.5 
BK 4.1 k2.9 6.1rt1.4 11.7~tO.2 - 29.4* 16.3 
Met-Lys-BK - 3.3Zt3.1 _ - - 
Biological activity of kinins released from high (HMMKs) and low molecular mass 
kininogens (LMMKs) and eluted from the HPLC column was measured by the rat 
uterus bioassay. Data are expressed as mean f SD. BK, bradykinin 
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Fig.1. HPLC separation of kinins. Separation of standard 
kinins (top two panels) and kinins released from high molecular 
mass kininogen (donor 1) by urinary kallikrein (bottom panel) 
was achieved by reverse-phase HPLC and isocratic conditions. 
Fractions of 0.5 ml were collected and the biological activity of 
kinins determined by the rat uterus bioassay is expressed as ng 
of bradykinin equivalents per, tube (O - - .o), The retention 
times of the kinin standards are given for comparison. 
DesArglBK, Des-Arg’-bradykinin; LBK, Lys-bradykinin; 
Ala4Kal1, [Ala4]-kallidin or [Ala3]-Lys-bradykinin; BK, 
bradykinin; MLBK, Met-Lys-bradykinin; T-Kinin, Ile-Ser- 
bradykinin; and x-BK, [Hyp3]-Lys-bradykinin. 
line. Thus, the sequence data, confirmed by FAB- 
mass spectrometry (not shown), revealed the struc- 
ture to be Lys-Arg-Pro-Hyp-Gly-Phe-Ser-Pro- 
Phe-Arg. 
Synthetic [Hyp3]-lysyl-bradykinin was obtained 
from the Max Planck Institute for Biochemistry 
(Martinsried, FRG). The synthetic peptide, whose 
structure was confirmed by amino acid sequence 
analysis and FAB-mass spectrometry (not shown), 
had an identical retention time upon HPLC 
separation to that of the fast eluting activity re- 
leased from the purified substrates. On a molar 
basis, both the native and synthetic 
[Hyp3]-lysyl-bradykinin contracted the rat uterus 
in a similar way to lysyl-bradykinin and exhibited 
a similar immunoreactivity. 
4. DISCUSSION 
This communication reports for the first time on 
the release of [Hyp3]-Lys-bradykinin from purified 
human kininogens by homologous urinary kalli- 
krein. Our findings support and extend those 
presented by others and ourselves at a meeting [6] 
and published very recently [7]. However, in these 
studies a crude substrate source was used. Purified 
kininogens also permitting the differentiation be- 
tween high and low molecular mass kininogens, 
and individual plasma donors for their preparation 
have not been employed. 
The common kinin moiety in human kininogens 
has the amino acid sequence Lys-Arg-Pro-Pro- 
Gly-Phe-Ser-Pro-Phe-Arg (Lys-bradykinin or 
kallidin). The finding of hydroxyproline in posi- 
tion 3 of the nonapeptide bradykinin does, 
therefore, not contradict the established sequence 
nor does it indicate genetic variation, since hydrox- 
ylation of proline is an intracellular posttransla- 
tional event which requires a specific hydroxylase 
and ferrous ions, molecular oxygen, (Y- 
ketoglutarate and ascorbic acid as cofactors [ 161. 
Hydroxylation of the proline next to glycine in the 
bradykinin sequence (Pro-Pro-Gly) within 
kininogens suggests that the specific enzyme is 
similar or identical to prolyl-C hydroxylase [16] 
acting upon kininogens as substrates. In fact, both 
bradykinin [ 171 and lysyl-bradykinin [ 181 can serve 
as substrates for prolyl hydroxylase in vitro, 
whereby hydroxylation is limited to only one of the 
three prolines in these molecules, the one in posi- 
tion 3. 
Upon incubation with purified, native single 
chain human low molecular mass kininogen, 
human urinary kallikrein releases primarily Lys- 
bradykinin (table 1). However, [Hyp3]-Lys-brady- 
kinin and bradykinin are released from this sub- 
strate preparation as well. In contrast, upon 
incubation with individual native single chain 
human high molecular mass kininogens obtained 
from four different donors, urinary kallikrein 
releases considerably more [Hyp3]-Lys-bradykinin, 
less Lys-bradykinin and a small amount of brady- 
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kinin (fig. 1, table 1). In each single preparation of 
high molecular mass kininogen the biological ac- 
tivity and immunoreactivity of [Hyp3]-Lys-brady- 
kinin represented more than 25% of the total 
kinins released. The observed difference in [Hyp3]- 
Lys-bradykinin content between high molecular 
mass kininogen and low molecular mass kininogen 
is unclear and can only be speculated upon. As 
deduced from the biosynthesis of collagen, the 
residue hydroxylated must be located in a peptide 
with a nonhelical conformation and long peptide 
substrates are more readily hydroxylated than are 
short peptides [16]. It is, therefore, interesting that 
high molecular mass kininogen is nearly double the 
size of low molecular mass kininogen due to its 
larger carboxy-terminal light chain and may 
possess multiple domains, each forming a loop 
structure [19]. However, since human low 
molecular mass kininogen has been purified from 
a pool of human plasma the amount of [proline3]- 
hydroxylation might also depend on the individual 
donors contributing to the plasma pool. 
The physiological significance of posttransla- 
tional hydroxylation of human kininogens is 
unknown. However, since the amount of hydrox- 
yproline acquired into the procollagen chains is re- 
quired for formation of the typical triple helix 
structure of functional collagen [ 161, hydroxyla- 
tion of proline in kininogen precursors might 
similarly influence the conformation and function 
of the secreted proteins. in this context, it could be 
speculated that such a hydroxylation might also in- 
fluence the versatile functions of kininogens in 
serving as a cofactor in contact activation of the 
Hageman factor-dependent pathways [20] or as 
thiol protease inhibitors [21,22] in addition to be- 
ing the kinin precursors. 
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